TABLE 1.

Characteristics of the included studies.

References	Stata	ASA	Sample size	Sex (Male/Female)	BMI (kg/m2)	Age (Years)	Interventions
Abdelhedi et al. (2023)	Tunisie	I-II	30	13/17	26.61 ± 3.85	50.97 ± 15.96	Dexamethasone
			30	7/23	27.11 ± 2.54	46.83 ± 10.78	Placebo
Labaille et al. (2002)	France	I-II	14	3/11	NA	53 ± 15	Ropivacaine
			12	4/8	NA	45 ± 18	Placebo
Honca et al. (2014)	Turkey	I-II	30	NA	NA	45.8 ± 14.1	Bupivacaine
			30	NA	NA	47.2 ± 13.2	Levobupivacaine
			30	NA	NA	44.63 ± 9.2	Placebo
Melidi et al. (2016)	Greece	I-II	36	19/17	26.9 ± 2.6	52 ± 13.7	Levobupivacaine
			37	18/19	26.2 ± 4.1	51.24 ± 14.3	Placebo
Nikoubakht et al. (2022)	Iran	I-II	19	5/14	25.65 ± 4.01	44.89 ± 11.41	Bicarbonate
			19	4/15	24.56 ± 2.89	46.84 ± 14.46	Marcaine
			20	5/15	24.49 ± 7.18	41.20 ± 13.38	Placebo
Putta et al. (2019)	India	I-II	28	11/17	25.0 ± 4.0	46.7 ± 8.7	Bupivacaine
			28	13/15	24.2 ± 3.2	41.0 ± 9.0	Placebo
Rahimzadeh et al. (2018)	Iran	I-II	20	NA	28.6 ± 1.8	45.5 ± 6.64	Bupivacaine
			20	NA	28.3 ± 1.9	44.3 ± 5.31	Acetazolamide
			20	NA	27.2 ± 1.9	47 ± 5.64	Placebo
Vijayaraghavalu and Bharthi Sekar (2021)	India	I-II	30	19/11	NA	39.8	Bupivacaine
			30	19/11	NA	40.13	Placebo
Sravanthi et al. (2023)	India	I-II	32	10/22	23.50 ± 2.1	42.59 ± 12.03	MgSO4
			32	12/20	24.25 ± 1.1	42.84 ± 11.32	Placebo
Beder El Baz and Farahat (2018)	Egypt	I-II	35	8/27	29.9 ± 6.9	NA	Levobupivacaine
			35	10/25	31 ± 6.2	NA	Placebo
Abdelaziz et al. (2021)	Egypt	I-II	25	7/18	NA	40.98 ± 15.33	Ondansetron
			25	5/20	NA	37.85 ± 13.17	Placebo

Abbreviation: ASA, american society of anesthesiologists; BMI, body mass index; NA, data Not Available.